GS vs RNTX · P/E 20, rev $58.28B vs $80.6M cap
Goldman Sachs Group Inc (GS) versus Rein Therapeutics Inc (RNTX) — a side-by-side from cached financials, not a winner call.
Goldman Sachs Group Inc (GS) is a capital markets company listed on NYSE. It is led by David M. Solomon.
Rein Therapeutics Inc (RNTX) is a biotechnology company listed on NASDAQ.
Latest reported GS revenue for 2025-12-31 was $58.28B. Net income was $17.18B. Revenue was up 8.9% from 2024-12-31 to 2025-12-31. GS currently screens at market cap $324.25B and trailing P/E 20.1.
Latest reported RNTX revenue for 2026-06-30 was $0. Net income was -$12.2M. RNTX currently screens at market cap $80.6M.
GS currently screens at market cap $324.25B and trailing P/E 20.1. RNTX currently screens at market cap $80.6M.
Not investment advice. Open the GS and RNTX stock pages for the full models.
Not investment advice.